These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 25469470)

  • 21. Vaccine-like nanomedicine for cancer immunotherapy.
    Yi Y; Yu M; Li W; Zhu D; Mei L; Ou M
    J Control Release; 2023 Mar; 355():760-778. PubMed ID: 36822241
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunotherapy: new insights].
    Geissler M; Weth R
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2236-46. PubMed ID: 12564040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor resistance to CD8+ T cell-based therapeutic vaccination.
    Huang Y; Shah S; Qiao L
    Arch Immunol Ther Exp (Warsz); 2007; 55(4):205-17. PubMed ID: 17659376
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines.
    Butt AQ; Mills KH
    Oncogene; 2014 Sep; 33(38):4623-31. PubMed ID: 24141774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA vaccines for cancer.
    Boyd D; Hung CF; Wu TC
    IDrugs; 2003 Dec; 6(12):1155-64. PubMed ID: 14666426
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Coupled for cross-presentation in tumor immunotherapy.
    Pang B; Neefjes J
    Sci Transl Med; 2010 Aug; 2(44):44ps40. PubMed ID: 20702855
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-localized delivery of nanomedicine and nanovaccine augments the postoperative cancer immunotherapy by amplifying T-cell responses.
    Liu X; Feng Z; Wang C; Su Q; Song H; Zhang C; Huang P; Liang XJ; Dong A; Kong D; Wang W
    Biomaterials; 2020 Feb; 230():119649. PubMed ID: 31791843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations.
    Hamdy S; Haddadi A; Hung RW; Lavasanifar A
    Adv Drug Deliv Rev; 2011 Sep; 63(10-11):943-55. PubMed ID: 21679733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. From cancer immunosurveillance to cancer immunotherapy.
    Stagg J; Johnstone RW; Smyth MJ
    Immunol Rev; 2007 Dec; 220():82-101. PubMed ID: 17979841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune responses to human tumors: development of tumor vaccines.
    Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS
    Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The emerging Protumor role of γδ T lymphocytes: implications for cancer immunotherapy.
    Rei M; Pennington DJ; Silva-Santos B
    Cancer Res; 2015 Mar; 75(5):798-802. PubMed ID: 25660949
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
    Mocellin S; Nitti D
    Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer immunotherapy: a treatment for the masses.
    Blattman JN; Greenberg PD
    Science; 2004 Jul; 305(5681):200-5. PubMed ID: 15247469
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor vaccine: current trends in antigen specific immunotherapy.
    Baral R
    Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanomedicine and cancer immunotherapy - targeting immunosuppressive cells.
    Torres Andón F; Alonso MJ
    J Drug Target; 2015; 23(7-8):656-71. PubMed ID: 26453162
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanomaterials for enhanced immunity as an innovative paradigm in nanomedicine.
    Seth A; Oh DB; Lim YT
    Nanomedicine (Lond); 2015; 10(6):959-75. PubMed ID: 25867860
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.
    Monjazeb AM; Hsiao HH; Sckisel GD; Murphy WJ
    J Immunotoxicol; 2012; 9(3):248-58. PubMed ID: 22734880
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer nanoimmunotherapy using advanced pharmaceutical nanotechnology.
    Li W; Wei H; Li H; Gao J; Feng SS; Guo Y
    Nanomedicine (Lond); 2014 Nov; 9(16):2587-605. PubMed ID: 25490427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance.
    Mapara MY; Sykes M
    J Clin Oncol; 2004 Mar; 22(6):1136-51. PubMed ID: 15020616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.